INTRODUCTION AND OBJECTIVES: Past attempts at contrast enhanced MRI (CE-MRI) of the bladder have been unable to enhance the image contrast between bladder wall and lumen in order to effectively resolve the bladder wall changes associated with cystitis or malignancy. Here we tested whether combined contrast-enhanced magnetic resonance imaging (CCE-MRI), using a mixture of Gadolinium and iron-oxide based contrast agent (ferumoxytol) is superior to CE-MRI in enhancing the image contrast of bladder wall. Each FDA approved agent in the contrast mixture is constituted of different particle size and have different contrast effects on the spin-echo imaging protocol.
INTRODUCTION AND OBJECTIVES: Past attempts at contrast enhanced MRI (CE-MRI) of the bladder have been unable to enhance the image contrast between bladder wall and lumen in order to effectively resolve the bladder wall changes associated with cystitis or malignancy. Here we tested whether combined contrast-enhanced magnetic resonance imaging (CCE-MRI), using a mixture of Gadolinium and iron-oxide based contrast agent (ferumoxytol) is superior to CE-MRI in enhancing the image contrast of bladder wall. Each FDA approved agent in the contrast mixture is constituted of different particle size and have different contrast effects on the spin-echo imaging protocol.
METHODS: Under isoflurane anesthesia, T1-weighted imaging of adult female Sprague-Dawley rat bladder was performed using standard turbo spin echo sequences at 7 Tesla, before and after transurethral instillation of 0.3 mL of single contrast (CE-MRI) or combined contrast mixture (CCE-MRI) composed of 0.4-64 mM of gadolinium chelate (Gadavist/Gd-DTPA) and 5 mM ferumoxytol. Bladder wall contrast was assessed in control group exposed to saline and in cystitis group exposed to 0.5 mL of protamine sulfate (10 mg/mL) for 30min RESULTS: CCE-MRI following instillation of 0.4-4 mM gadavist (gadolinium ) and 5 mM ferumoxytol mixture was superior to CE-MRI (instillation of either Gadavist or ferumoxytol) in achieving the maximum contrast between the lumen and bladder wall. T1-relaxation enhancement in bladder lumen by gadavist is masked by the T2 effect from localization of the larger ferumoxytol nanoparticles in the lumen, but the diffusion of gadavist into the lesions caused by protamine is marked by the hyperintense signal in bladder wall. The normalized hyperintensity in the bladder wall increased from 0.46 AE0.07 in control group to 0.73AE 0.14 in the protamine group (p < 0.0001).
CONCLUSIONS: CCE-MRI following instillation of the contrast mixture is superior to CE-MRI using individual contrast agents in the visualization of bladder wall changes likely associated with cystitis or malignancy. CCE-MRI relies on differences in particle size and contrast mechanisms of gadolinium chelates and ferumoxytol. This novel approach has the potential to distinguish diffuse versus a focal disruption in the bladder wall integrity of interstitial cystitis patients, facilitating accurate diagnosis and improved patient care. Patients with interstitial cystitis (IC)/bladder pain syndrome (BPS) are often provided narcotic therapy as part of a multimodal approach. Some of these patients may progress to cystectomy with urinary diversion (CWUD), but the impact upon long-term narcotic usage is unknown. We sought to determine the rate of persistent narcotic usage among IC/BPS patients undergoing CWUD.
METHODS: An IRB-approved, prospectively collected singlesurgeon database of IC/BPS patients who underwent CWUD from April 2010 to April 2016 was reviewed. Patients residing outside of NC were excluded. The remainder was queried via the North Carolina Controlled Substance Reporting System, which tracks all statewide dispensing of Schedule II-V substances. Cases were evaluated for the total amount of dispensed substances for the year prior to surgery and up to one year postoperatively, and converted to oral morphine equivalents. The difference in usage was compared by a Student's 2-tailed t-test. Prescriptions filled within the first 30 days after surgery were excluded.
RESULTS: 32 patients met inclusion criteria, 84.3% of which had additional chronic pain disorders. Mean age was 55 years and mean preoperative anesthetic bladder capacity was 433 cc. Mean follow-up was 744 days. All patients were narcotic users preoperatively. Following CWUD, 25/32 (78%) patients filled database-registered prescriptions after the 30-day postoperative window. The most commonly dispensed oral narcotics were oxycodone and hydrocodone. Compared to preoperative totals, mean postoperative morphine equivalents decreased by 52.6% (NS; p ¼ 0.254). Two patients initiated therapy with fentanyl patches in the year after surgery.
CONCLUSIONS: Following CWUD for IC/BPS, 78% of patients can be expected to continue narcotic therapy. Although mean usage appears to decrease postoperatively, the difference was not significant, and may be related to the prevalence of coexisting pain disorders in this population. This information is critical to setting patient expectations and for educating state medical boards. Future work is necessary to determine whether postoperative substance usage is potentially related to withdrawal and if alternative regimens are feasible.
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PD01-10 EFFECTS OF REPEAT HYDRODISTENTION FOR INTERSTITIAL CYSTITIS
INTRODUCTION AND OBJECTIVES: Cystoscopy and hydrodistention is a therapeutic procedure for interstitial cystitis (IC) which achieves symptomatic relief in many patients, though its use varies widely between providers. The long term effects of repeated hydrodistention are not well understood and it is not known if patients suffer a reduction in bladder capacity due to these multiple procedures or develop ulcerating disease over time. We sought to investigate the effects of multiple hydrodistentions in patients with IC.
METHODS: We retrospectively queried our institutional records for patients without ulcerative disease who underwent 2 or more hydrodistentions for IC over a ten year period. Patient charts were reviewed for demographic and clinical factors at the time of diagnosis and treatment.
RESULTS: There were 97 patients who underwent multiple cystoscopy and hydrodistention procedures for non ulcerative IC during the ten year study period. The cohort was 98% female and 92% Caucasian. Mean age at diagnosis was 35.7 years, and mean BMI was 27.1. Average number of procedures performed was 3.7 (range 2 to 18), and mean time between procedures was 430.6 days. Within this cohort 63.3% of patients had at least 1 comorbid pain disorder. Mean initial and final anesthetic bladder capacity were 723.9cc and 753.1cc, respectively, which were not significantly different (p¼0.15). One patient in this cohort later developed ulcerative disease which was not present at initial cystoscopy. Among patients who completed AUA symptom questionnaires before and after hydrodistention, both symptom and quality of life scores were significantly improved following treatment Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e49
